Literature DB >> 11161723

Use of galactosyltransferase to assess the biological function of O-linked N-acetyl-d-glucosamine: a potential role for O-GlcNAc during cell division.

B Fang1, M W Miller.   

Abstract

Many cytosolic and nuclear proteins are modified by monomeric O-linked N-acetyl-d-glucosamine (O-GlcNAc). The biological functions of this form of glycosylation are unclear but evidence suggests that it heightens regulation of protein function. To assess the biological function of O-GlcNAc addition, we examined the biological effects of galactosyltransferase (GalT) microinjected into the cytoplasm of Xenopus ovarian oocytes. GalT, which catalyzes beta1-4-galactose addition to O-GlcNAc, should inhibit deglycosylation and lectin-like interactions requiring unmodified O-GlcNAc residues. Although GalT injection into diplotene-arrested oocytes has no detectable effects on cell viability, it is toxic to oocytes entering meiosis. Cell-cycle-specific toxicity is recapitulated in vitro as GalT inhibits formation of nuclei and microtubule asters from cell-free extracts of ovulated frog eggs. These observations suggest that regulation of O-GlcNAc is important for cell cycle progression and may be important in diseases in which O-GlcNAc metabolism is abnormal. The methods described here outline a viable experimental scheme for ascribing a biological function to this form of glycosylation. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11161723     DOI: 10.1006/excr.2000.5110

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  11 in total

Review 1.  The sweet side of the cell cycle.

Authors:  Ee Phie Tan; Francesca E Duncan; Chad Slawson
Journal:  Biochem Soc Trans       Date:  2017-04-15       Impact factor: 5.407

2.  Brain O-GlcNAcylation: From Molecular Mechanisms to Clinical Phenotype.

Authors:  Batuhan Uygar; Olof Lagerlöf
Journal:  Adv Neurobiol       Date:  2023

Review 3.  Glycosylation of the nuclear pore.

Authors:  Bin Li; Jennifer J Kohler
Journal:  Traffic       Date:  2014-02-13       Impact factor: 6.215

4.  Survey of O-GlcNAc level variations in Xenopus laevis from oogenesis to early development.

Authors:  Vanessa Dehennaut; Tony Lefebvre; Yves Leroy; Jean-Pierre Vilain; Jean-Claude Michalski; Jean-François Bodart
Journal:  Glycoconj J       Date:  2008-07-17       Impact factor: 2.916

5.  A mitotic GlcNAcylation/phosphorylation signaling complex alters the posttranslational state of the cytoskeletal protein vimentin.

Authors:  Chad Slawson; T Lakshmanan; Spencer Knapp; Gerald W Hart
Journal:  Mol Biol Cell       Date:  2008-07-23       Impact factor: 4.138

6.  Reduced O-GlcNAcase expression promotes mitotic errors and spindle defects.

Authors:  Chris Lanza; Ee Phie Tan; Zhen Zhang; Miranda Machacek; Amanda E Brinker; Mizuki Azuma; Chad Slawson
Journal:  Cell Cycle       Date:  2016-05-18       Impact factor: 4.534

7.  Human linker histones: interplay between phosphorylation and O-β-GlcNAc to mediate chromatin structural modifications.

Authors:  Waqar Ahmad; Khadija Shabbiri; Noreen Nazar; Shazia Nazar; Saba Qaiser; Mirza Abid Shabbir Mughal
Journal:  Cell Div       Date:  2011-07-12       Impact factor: 5.130

Review 8.  A little sugar goes a long way: the cell biology of O-GlcNAc.

Authors:  Michelle R Bond; John A Hanover
Journal:  J Cell Biol       Date:  2015-03-30       Impact factor: 10.539

9.  Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation.

Authors:  Francesca Ricciardiello; Yang Gang; Roberta Palorini; Quanxiao Li; Marco Giampà; Fangyu Zhao; Lei You; Barbara La Ferla; Humberto De Vitto; Wenfang Guan; Jin Gu; Taiping Zhang; Yupei Zhao; Ferdinando Chiaradonna
Journal:  Oncogene       Date:  2020-03-31       Impact factor: 9.867

10.  O-GlcNAcylation: A New Cancer Hallmark?

Authors:  Yann Fardini; Vanessa Dehennaut; Tony Lefebvre; Tarik Issad
Journal:  Front Endocrinol (Lausanne)       Date:  2013-08-12       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.